Monoclonal antibody · developed by Sanofi
Duvakitug (SAR447189, TEV-48574) is a drug given by subcutaneous injection, supplied as a solution for injection. It is studied in Crohn disease and ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07184996 | Phase 3 | Ulcerative Colitis | Recruiting | SNY |
| NCT05668013 | Phase 2 | Crohn Disease | Active not recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colitis, UlcerativeCrohn DiseaseUlcerative Colitis
Updated Nov 22, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →